• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Efficacy and safety of Revlimid combined with Rituximab in the treatment of follicular lymphoma: A meta-analysis

    2023-12-06 07:54:42WuYoujiaoLiuLinBIXiaomanZHENGShaojiang
    Journal of Hainan Medical College 2023年15期
    關鍵詞:濾泡淋巴瘤單抗

    Wu You-jiao, Liu Lin, BI Xiao-man,2?, ZHENG Shao-jiang?

    1.Tumor Institute, the First Affiliated Hospital of Hainan Medical University, Haikou 570102, China

    2.College of Biomedical Information and Engineering, Hainan Medical University, Haikou 571199, China

    Keywords:

    ABSTRACT Objective: To evaluate the clinical efficacy and safety of lenalidomide combined with rituximab for treating follicular lymphoma.Methods: We searched PubMed, Web of Science,Cochrane Library, Embase, China Medical Biological Service system (CBM), VIP database(VIP), Wan fang database (Wan Fang Data), China Knowledge Network (CNKI), and ClinicTrails.gov for literature related to lenalidomide combined with rituximab for treating follicular lymphoma (until June 23, 2022).The literature that met the requirements were screened out according to the established criteria, and the data were analyzed by RevMan5.4 and Stata14.0 to conduct a meta-analysis.Results: Eight studies involving 865 patients with follicular lymphoma were included.The results of the meta-analysis showed that the objective remission rate (RR = 1.43, 95% CI: 1.26–1.61) and complete remission rate (RR = 1.67, 95%CI: 1.27–2.21) of lenalidomide combined with rituximab for treating follicular lymphoma were

    1.Introduction

    Follicular lymphoma (FL) is the most common inert lymphoma and the second most common non-Hodgkin’s lymphoma (NHL).FL is characterized by diffuse lymph node enlargement, bone marrow involvement, and splenomegaly, and has a significant biological and clinical heterogeneity[1].The progress of FL is slow and the survival time is long.Moreover, few patients in the early stage of disease can be cured by radiotherapy[2].Because the advent of the anti-CD20 monoclonal antibody rituximab, the survival of patients with recurrent or refractory FL has been improved, and the survival time has been extended to 20 years[3, 4].However, some patients have a risk of recurrence and transformation into invasive lymphoma, with poor prognosis[5].Increasing evidence has shown that the tumor microenvironment (TME) participates in the disease progression and drug resistance of B-cell malignant tumors by promoting tumor growth and helping malignant cells to escape immune recognition.Immunomodulatory drugs (such as lenalidomide) not only have direct anti-tumor activity but also target various cells in the TME,including T cells, NK cells, and stromal cells by interfering with tumor signal transduction and activating the anti-tumor immune response[6, 7].Lenalidomide has achieved good clinical results as a single drug for treating tumors, and combined therapy can produce a lasting response to FL.Although most patients are initially treated with lenalidomide combined with rituximab, its efficacy and safety need to be further verified.

    Here, we conducted a meta-analysis to evaluate the efficacy and safety of lenalidomide combined with rituximab for treating FL,to explore the relevant research at home and abroad, summarize the relevant conclusions, and provide strong data support for evidencebased medicine to guide clinical decision-making.

    2.Materials and methods

    2.1 Selection criteria

    2.1.1 Inclusion criteria

    Research types: randomized controlled trials, non-randomized controlled trials, and single-arm clinical trials published at home and abroad on lenalidomide combined with rituximab for treating FL, limited to Chinese and English, irrespective of the blind method and published status; subjects: patients with FL diagnosed by pathological examination, regardless of sex, race, age, disease stage,and previous treatment; intervention: lenalidomide combined with rituximab used to treat FL in the experimental group, and rituximab alone was used to treat FL in the control group; outcome indicators:the objective and complete remission rates were employed as effectiveness indicators, and adverse reactions were used as safety indicators.

    2.1.2 Exclusion criteria

    Duplicate studies, reviews, case reports, and studies in which the number of patients in the study group was < 10; animal experiments and basic research; literature in which the research content or outcome index was inconsistent with the inclusion criteria; the research design was not rigorous, or the treatment or intervention measures were not related to the experiment; and the data were incorrect.

    2.2 Literature retrieval

    Web of Science, Embase, PubMed, The Cochrane Library, China Medical Student Material Service system, China Knowledge Network, VIP database, Wan fang database, and ClinicTrails.gov were searched for relevant literature.The publication time of the literature was from the inception of the database until June 23, 2022.The search words were a combination of subject and free words.The Chinese keywords included “來那度胺,” “利妥昔單抗,” and “濾泡性淋巴瘤,” while the English keywords included “Revlimid,”“IMiD3 Cpd,” “CC5013,” “CC5013,” “CC-5013,” “Revlimid,”“Rituximab,” “CD20 Antibody, Rituximab,” “Rituximab CD20 Antibody,” “Mabthera,” “Lymphoma, Follicular,” and “Follicular Lymphomas,” among others.

    2.3 Data extraction and methodological quality evaluation

    2.3.1 Data extraction

    All of the relevant retrieved literature were imported into the EndNote software, the software management program was used to integrate the literature, and the literature related to this research topic was screened out.Two evaluators independently screened the titles and abstracts of all studies acquired during the literature retrieval and analyzed whether they met the selection criteria.In cases where this information could not be accurately judged, the full text was first obtained to determine whether the study should be included.If this could not be established from the full text review, a consensus was reached through discussion or based on the judgment of a third researcher.

    2.3.2 Quality assessment

    The Cochrane bias quality risk assessment tool was used to evaluate the quality of RCT literature, including whether it accorded with random sequence distribution, whether it accorded with the concealment of distribution mode, whether it blinded the experimenter or researcher, whether it lacked the outcome index,whether it reported the experimental results, and whether other biases existed.The above statistical data were evaluated at three levels: “high-risk bias,” “l(fā)ow-risk bias,” and “uncertain risk bias.”For literature on non-RCTs and single-arm experimental studies,MINORS evaluation terms were selected for quality evaluation, as shown in our previous research methods[8]: A total of 12 evaluation indicators were used, of which the first eight applied to the study without a control group, each with a score of 0~2, in which 0 indicated “unreported,” 1 indicated “reported but insufficient information,” and 2 indicated “reported and provides sufficient information,” and thus, full marks for the first eight indicators would total 16 points.According to the MINORS evaluation table, only studies with a total score ≥ 13 were included in the meta-analysis.

    2.4 Statistical analysis

    RevMan5.4 and Stata15 software were used to analyze the data.Q-test was employed to evaluate the heterogeneity of the study, and P values < 0.05 were considered statistically different.The fixed effect model whenI250%, indicating good homogeneity between the studies; in contrast, if the heterogeneity of each study was large,we first analyzed the causes of the heterogeneity, before making reasonable analysis and judgment according to the specific situation.In cases where the cause of heterogeneity was easily obtained,the random effect model was employed to analyze and make a descriptive explanation; in contrast, when the data heterogeneity was too large to make a reasonable explanation, the cause of heterogeneity was investigated through sensitivity or subgroup analysis.The relative risk ratio (RR) and its 95% confidence interval(CI) were used for the analysis of the objective response rate (ORR)and complete response rate (CRR) in RCT, and the risk difference(RD) and its 95% CI were used for the analysis of the objective remission rate, complete remission rate, and all adverse reactions in the non-RCTs.Adverse reactions were defined as any adverse events that occurred during treatment.The funnel chart was used to investigate the presence of publication bias in the results.

    3.Results

    3.1 Literature screening process and results

    Through a preliminary search of subject words, a total of 413 articles were retrieved.Based on the screening criteria (Fig.1), eight articles[9-16] were included in this study, including seven English articles[9-15] and one Chinese article[16].

    3.2 Basic characteristics of the included literature and bias risk assessment

    Among the eight included studies, the research data were more complete.After summarizing the basic characteristics of the studies,we found no significant difference in age, tumor stage, course of treatment, and treatment strategy between the experimental and control groups.Five articles[9, 10, 12, 14, 16] were single-arm studies,and three[11, 13, 15] were RCTs (the control group participated in the statistical study of single-arm trials).The trial groups of eight studies were treated with lenalidomide combined with rituximab, and the control groups of three studies were treated with rituximab with or without placebo.The basic characteristics of the control group included in the study are detailed in Table 1.According to the items of the Cochrane bias quality risk assessment tool (see Fig.2 for details).

    Tab 1 Characteristics of the included studies

    Fig 2 Summary of risk of bias

    3.3 Meta-analysis results

    3.3.1 Objective remission rate

    3.3.1.1 Meta-analysis with a single-arm test method

    Seven articles[10-16] met the criteria of the meta-analysis, involving 865 patients, including 296 patients with ORR.The fixed effect model was used for the meta-analysis of the single-arm dichotomous data.The results showed that I2= 0 < 50%, P = 0.76 > 0.05.The analysis showed that the combined effect test of RD =[0.87, 95% CI= [0.79, 0.96],Z= 20.17 was statistically significant (P< 0.00001).The results showed that lenalidomide combined with rituximab was effective in treating FL, with an objective remission rate of 87%.

    3.3.1.2 Meta-analysis according to the experimental method of the control group

    A total of 543 patients were included in the three articles[11, 13, 15]that met the requirements of analysis, including the treatment group(n= 270) and control group (n= 273).Analysis of the fixed effect model showed that I2= 0 < 50%, P = 0.79 > 0.05, RR = 1.43, and 95% CI: [1.26, 1.61], while the combined effect test showed Z = 5.76P< 0.00001, which was statistically significant (see Fig.4).These results suggest that the objective remission effect of lenalidomide combined with rituximab for treating FL is better than that of the control group.

    Fig 3 Meta-analysis on the ORR of Revlimid plus Rituximab for treating FL

    Fig 4 Meta-analysis on the ORR of Revlimid plus Rituximab for treating FL in RCT

    3.3.2 Complete remission rate

    3.3.2.1 Meta-analysis with a single-arm test method

    Seven articles[10-16] met the criteria for analysis, involving 865 patients, including 296 patients with CR.The random effect model was used to conduct a meta-analysis of the single-arm dichotomous data, withI2= 81% > 50%.The large heterogeneity was found to be caused by the inclusion of more single-arm studies.The analysis obtained RD = 0.58, 95% CI = [0.50,0.67], while the combined effect test showedZ= 13.48,P< 0.00001; the result was statistically significant (Fig.5).Lenalidomide combined with rituximab may be effective for treating FL, with a complete remission rate of 58%.However, more high-quality randomized trials need to be included.

    3.3.2.2 Meta-analysis according to the experimental method of the control group

    The information on 543 patients was included in three articles[11,13, 15], including 270 cases in the treatment group and 273 cases in the control group.The fixed effect model analysis showed that I2=0 < 50%,P= 0.79 > 0.05.TheRR= 1.67 and 95%CI= [1.27,2.21]were obtained by the analysis, and the combined effect test showed Z = 3.62, which was statistically significant (Fig.6).The objective remission effect of lenalidomide combined with rituximab for treating FL was better than that of rituximab alone and better than that of the control group.

    Fig 5 Meta-analysis on the CR of Revlimid plus Rituximab for treating FL

    Fig 6 Meta-analysis on the CR of Revlimid plus Rituximab for treating FL in RCT

    3.3.3 Main adverse reactions

    Eight articles[9-16] selected in this study reported the main adverse reactions from ten aspects, including neutropenia, lymphopenia,thrombocytopenia, anemia, fatigue, diarrhea, nausea and vomiting,rash, infection, and thrombosis.The results of the subgroup analysis of different evaluation criteria are shown in Fig.7.

    Statistical analysis of the data in the reported neutropenia literature[9, 11, 12, 14, 16] showed thatP= 0.06 < 0.1,I2= 54%> 50%, with moderate heterogeneity.Using the random effect model, the effect doseRD= 0.33, 95%CI= [0.18, 0.49], while the Q test showedP< 0.0001, which was statistically significant.Approximately 33% of patients have adverse reactions to neutropenia during the treatment of FL with lenalidomide combined with rituximab.

    Based on the statistical analysis of the data in the literature on lymphopenia[11, 12, 15, 16], the results showed thatP< 0.01,I2=78% > 50%, with large heterogeneity.Analysis using the random effect model showed RD = 0.21, 95% CI: = [0.06 and 0.48], and no statistical significance in the Q test (P= 0.13 > 0.05).

    Statistical analysis reported the data of thrombocytopenia[9, 11, 12,15, 16] in the literature.The results showed that P > 0.01, I2= 47% <50%, with low heterogeneity, while the fixed effect model showed the effect doseRD= 0.15, 95%CI= [0.02, 0.32], passed the Q test(P = 0.09 > 0.05), and had no statistical significance.

    Based on the statistical analysis of the data in the literature reporting anemia[9, 12, 15], the results showed thatP< 0.01,I2= 59 >50%, which was evaluated as moderate heterogeneity; the random effect model showed that the effect wasRD= 0.17, 95%CI: = [0.05,0.38], with no statistical significance according to the Q test (P>0.05).

    According to the statistical analysis of the data of the literature on fatigue, the results showed thatP< 0.0001,I2= 82% > 50%,indicating high heterogeneity.Therefore, a random effect model was adopted, the results of which demonstrated RD = 0.37, 95%CI= [0.12, 0.62], andP= 0.004 < 0.05.Moreover, approximately 37% of patients developed symptoms of fatigue during treatment with lenalidomide combined with rituximab for FL.However, the heterogeneity was high, possibly due to the number of articles included in more single-arm studies; therefore, it is necessary to include more high-quality randomized experimental studies in the future.

    Statistical analysis of the data related to diarrhea[9, 12, 15] showed that P > 0.01, I2= 0% < 50%, with low heterogeneity.The results of the fixed effect model demonstrated that the effect amountRD= 0.29, 95%CI: = [0.16, 0.43], andP< 0.0001.Moreover,approximately 29% of patients developed diarrhea during treatment with lenalidomide combined with rituximab for FL.

    Statistical analysis of the data related to nausea or vomiting in the literature[9, 12, 15] showed that P > 0.01, I2= 0% < 50%, and low heterogeneity.The results of the fixed effect model demonstrated that the effect amountRD= 0.17, 95%CI= [0.04, 0.31], andP<0.05.Lenalidomide combined with rituximab for FL was associated with a 17% chance of causing nausea or vomiting.

    Statistical analysis of the data of the literature reporting rash events[9, 11, 12, 14-16] showed that P = 0.35 > 0.01, I2= 10% < 50%,with low heterogeneity.The results of the fixed effect model showed thatRD= 0.20, 95%CI= [0.09, 0.31],P< 0.05.Furthermore,approximately 20% of the patients developed a rash during treatment with FL and lenalidomide combined with rituximab.

    Based on the data of selected literature related to infection[11-13,15,16], the fixed effect model showed that P = 0.37 > 0.01, I2= 6%< 50%, low heterogeneity,RD= 0.11, 95%CI= [0.01, 0.23],P=0.08 > 0.05, and no statistical significance.The data related to thrombus from selected literature[13,15,16] were analyzed by the fixed effect model, which demonstratedP= 0.89 >0.01,I2= 0% < 50%, low heterogeneity,RD= 0.04, 95%CI= [0.13,0.20],P= 0.67 > 0.05, and no statistical significance.

    Fig 7 Meta-analysis on adverse events of Revlimid plus rituximab for treating FL

    3.4 Bias analysis

    The objective remission rate (Fig.8A) and complete remission rate (Fig.8B) were analyzed by Stata14.0, and the figures were symmetrical.We conducted a symmetry test of the above two pictures (Figs.8C–D), P = 0.051 > 0.05, P = 0.946 > 0.05, and the results showed that the funnel diagram was basically symmetrical,suggesting no obvious publication bias in the literature of this study.

    4.Discussion

    Lenalidomide, as a targeted immunomodulatory drug combined with rituximab, has become a new treatment option for recurrent FL, including patients who show inadequate responses to rituximab alone, and those who wish to avoid cytotoxic chemotherapy[17].In the phase III AUGMENT trial, lenalidomide + rituximab significantly prolonged PFS in patients with recurrent or refractory inert NHL compared to placebo + rituximab, and the PFS benefit was prominent in patients with FL.Lenalidomide + rituximab also showed significant activity in the phase III MAGNIFY trials in patients with recurrent or refractory inert NHL, including those with disease that was refractory to rituximab [18,19].Although grade 3 or 4 neutropenia occurred more frequently in the lenalidomide +rituximab group than in the placebo + rituximab group, it could be controlled by adjusting the dose.However, there remains a lack of high-level clinical evidence for its therapeutic efficacy and safety.

    Accordingly, the efficacy and safety of lenalidomide combined with rituximab for treating FL were evaluated by a meta-analysis.Combined with single-arm and control group experiments, compared to rituximab alone for treating FL, the objective remission rate and complete remission rate of lenalidomide combined with rituximab for treating FL were significantly improved.During treatment, the risk of adverse reactions, such as neutropenia, diarrhea, nausea and vomiting, and rash, was relatively high, but the overall proportion is at a low level, so it is necessary to make corresponding treatment for the related adverse reactions.In view of these adverse reactions,the existing medical level can be improved or inhibited to varying degrees by drugs or other means.Additionally, due to the high heterogeneity of adverse reaction indices, such as lymphocytopenia and fatigue, more controlled trials need to be included for further exploration.

    The purpose of this study was to demonstrate the clinical effect of lenalidomide in treating FL.Previous studies have shown heterogeneity in the treatment regimen and duration of patients with different subtypes of B-cell lymphoma.Here, clinical studies on FL were screened strictly according to the inclusion criteria to avoid the risk of greater heterogeneity after analysis with other types of NHLs,including diffuse large B-cell lymphoma, mantle cell lymphoma,and primary central nervous system lymphoma.Additionally, the drugs involved in this experiment were relatively consistent, which confirms the actual clinical efficacy after the control variables.

    This study had some limitations.First, some of the included studies were single-arm, which may lead to a certain degree of deviation in the results.Second, the small sample size may lead to a certain risk of bias, which requires the inclusion of, large-sample, multicenter clinical randomized controlled trials in the future.Third,although the intervention measures in the literature study were set as lenalidomide combined with rituximab for the treatment of FL, differences in the dosage and cycle among the studies may have a certain impact on the results of the meta-analysis.Fourth,although the relevant data were collected comprehensively, due to the different outcome indicators in different studies, some outcome indicators could not be integrated and analyzed.Fifth, as only Chinese and English literature were included, the literature was not comprehensive and the inclusion of ethnic groups was limited.Sixth, a few of them have been included in the literature for a long time, but the disease is in the process of continuous development and variation, so there may be some limitations in the significance of clinical guidance.Finally, publication bias inevitably occurred in the literature, because studies with statistically significant results were relatively easy to publish, while those with negative results were not.Therefore, more well-designed prospective large-sample, multicenter randomized controlled trials are needed to re-analyze and evaluate the effectiveness and safety of this study.

    Currently, lenalidomide combined with rituximab or rituximab alone is the standard first-line or follow-up treatment option for advanced FL, while other treatment options (e.g., PI3K inhibitors,tazemestostat, and CAR-T cell therapy) continue to evolve[2].Studies have shown that several small molecular inhibitors involved in the proliferation of PI3 kinase and BTK have anti-FL activity[20,21].Additionally, the EZH2 inhibitor tazemestostat was approved by the FDA for FL after previous second-line treatment[22].Notably,chimeric antigen receptor T cells (CART) or bispecific antibody constructors have a unique therapeutic mechanism in FL[23, 24].In view of these potential non-cross-reaction mechanisms, the design and optimization of combination strategies are expected to improve the outcome of FL, and may even achieve a cure.Therefore, at present, there is still an urgent need for personalized methods, trial endpoints for quality of life measurement, guidance on available schemes, and information on drug sequencing[25].The research and development of new drugs and the continuous discovery of the pathogenic mechanism of FL are expected to improve the prognosis and quality of life of patients with FL.

    In this study, compared to the CD20 antibody rituximab alone,lenalidomide combined with rituximab showed greater efficacy in alleviating FL.Although the combination may bring some side effects, such as neutropenia, nausea, vomiting, and rash, most can be relieved by providing symptomatic treatment or adjusting the drug dose to reduce the occurrence of symptoms.

    猜你喜歡
    濾泡淋巴瘤單抗
    HIV相關淋巴瘤診治進展
    傳染病信息(2022年3期)2022-07-15 08:24:12
    超聲診斷甲狀腺濾泡型腫瘤的研究進展
    司庫奇尤單抗注射液
    認識兒童淋巴瘤
    高頻甲狀腺超聲對濾泡性腫瘤的診斷價值
    曲妥珠單抗治療后進展的轉移性乳腺癌繼續(xù)曲妥珠單抗治療的療效及安全性分析
    癌癥進展(2016年12期)2016-03-20 13:16:10
    使用抗CD41單抗制備ITP小鼠的研究
    鼻咽部淋巴瘤的MRI表現(xiàn)
    磁共振成像(2015年5期)2015-12-23 08:52:50
    甲狀腺乳頭狀癌濾泡亞型聲像圖及臨床病理特征分析
    原發(fā)性甲狀腺淋巴瘤1例報道
    看免费av毛片| 欧美一区二区精品小视频在线| a级一级毛片免费在线观看| 免费人成在线观看视频色| 欧美日韩国产亚洲二区| 免费av不卡在线播放| 国产白丝娇喘喷水9色精品| 少妇熟女aⅴ在线视频| 欧美日韩瑟瑟在线播放| 免费无遮挡裸体视频| 亚洲最大成人中文| a级毛片a级免费在线| 成人午夜高清在线视频| 欧美色视频一区免费| 18禁黄网站禁片午夜丰满| av女优亚洲男人天堂| 久久久国产成人免费| 1024手机看黄色片| 99在线视频只有这里精品首页| 极品教师在线视频| 国内精品久久久久久久电影| 一本一本综合久久| 午夜老司机福利剧场| 久久久国产成人免费| 欧美日韩福利视频一区二区| 午夜老司机福利剧场| 午夜老司机福利剧场| 给我免费播放毛片高清在线观看| 国产真实乱freesex| 熟女人妻精品中文字幕| 亚洲欧美日韩高清专用| 能在线免费观看的黄片| 国产视频内射| 成年人黄色毛片网站| 午夜激情欧美在线| 美女高潮的动态| 久久精品国产99精品国产亚洲性色| 欧美极品一区二区三区四区| 免费在线观看成人毛片| 真人一进一出gif抽搐免费| 国模一区二区三区四区视频| 色精品久久人妻99蜜桃| 色在线成人网| 日韩人妻高清精品专区| 在线观看舔阴道视频| h日本视频在线播放| 好看av亚洲va欧美ⅴa在| 欧美最新免费一区二区三区 | 欧美绝顶高潮抽搐喷水| 国产午夜福利久久久久久| 久久精品国产自在天天线| 日韩欧美一区二区三区在线观看| 欧美黄色片欧美黄色片| 久久99热这里只有精品18| 精品午夜福利在线看| www.999成人在线观看| 99国产综合亚洲精品| 岛国在线免费视频观看| 在现免费观看毛片| 熟女人妻精品中文字幕| 亚洲av不卡在线观看| 极品教师在线视频| 亚洲av电影不卡..在线观看| 亚洲精品乱码久久久v下载方式| 午夜精品一区二区三区免费看| 日韩欧美在线二视频| 日韩欧美在线二视频| 日韩欧美国产在线观看| 国产探花在线观看一区二区| 欧美乱色亚洲激情| 成人高潮视频无遮挡免费网站| 亚洲无线观看免费| 精品一区二区三区视频在线观看免费| 免费在线观看影片大全网站| 97人妻精品一区二区三区麻豆| a级毛片免费高清观看在线播放| 天美传媒精品一区二区| 亚洲av第一区精品v没综合| 国产精品女同一区二区软件 | 国产一区二区三区在线臀色熟女| 欧美性感艳星| 久久九九热精品免费| 精品无人区乱码1区二区| 亚洲欧美精品综合久久99| 日本三级黄在线观看| 9191精品国产免费久久| 精品一区二区三区视频在线观看免费| 日韩中字成人| 午夜影院日韩av| 国产不卡一卡二| 久久久久久久久大av| 淫秽高清视频在线观看| 亚洲精品影视一区二区三区av| 美女cb高潮喷水在线观看| 国产亚洲欧美98| 小蜜桃在线观看免费完整版高清| 波野结衣二区三区在线| 日本黄色视频三级网站网址| 神马国产精品三级电影在线观看| 一a级毛片在线观看| 国产成人福利小说| 嫩草影院入口| 麻豆成人午夜福利视频| 成年女人毛片免费观看观看9| 97超级碰碰碰精品色视频在线观看| 一级黄片播放器| 精品久久久久久久久久久久久| 波多野结衣巨乳人妻| 不卡一级毛片| 亚洲真实伦在线观看| 免费电影在线观看免费观看| 国产黄色小视频在线观看| 热99re8久久精品国产| 99久久无色码亚洲精品果冻| 精品熟女少妇八av免费久了| 免费看日本二区| 赤兔流量卡办理| 日本黄大片高清| 美女免费视频网站| 欧美黑人欧美精品刺激| av视频在线观看入口| 免费在线观看成人毛片| 欧美丝袜亚洲另类 | 一个人观看的视频www高清免费观看| 禁无遮挡网站| 国产单亲对白刺激| 日本一本二区三区精品| 黄色配什么色好看| 久久国产乱子伦精品免费另类| 国产主播在线观看一区二区| 听说在线观看完整版免费高清| 亚洲av免费高清在线观看| 一卡2卡三卡四卡精品乱码亚洲| 内射极品少妇av片p| 悠悠久久av| 日本五十路高清| 少妇的逼好多水| 日韩av在线大香蕉| xxxwww97欧美| 亚洲天堂国产精品一区在线| 欧美最黄视频在线播放免费| 老熟妇乱子伦视频在线观看| 亚洲真实伦在线观看| 亚洲内射少妇av| 成人av在线播放网站| 高清在线国产一区| 天天一区二区日本电影三级| 亚洲成人久久性| 在线国产一区二区在线| 国产精品一区二区三区四区免费观看 | 九色国产91popny在线| 少妇的逼水好多| 波野结衣二区三区在线| 九九久久精品国产亚洲av麻豆| 舔av片在线| 我要看日韩黄色一级片| 男插女下体视频免费在线播放| 老女人水多毛片| 色5月婷婷丁香| 搡老岳熟女国产| 亚洲国产欧美人成| 啪啪无遮挡十八禁网站| 欧美黄色淫秽网站| 欧美日韩国产亚洲二区| 一区二区三区高清视频在线| 久久精品影院6| 国产一区二区亚洲精品在线观看| 日本 欧美在线| 美女高潮的动态| 美女被艹到高潮喷水动态| 久久热精品热| 亚洲精品色激情综合| 免费搜索国产男女视频| 国产v大片淫在线免费观看| netflix在线观看网站| 99视频精品全部免费 在线| 久久久久亚洲av毛片大全| 国产高清激情床上av| 欧美性感艳星| 老司机午夜福利在线观看视频| 小蜜桃在线观看免费完整版高清| 日韩欧美 国产精品| 亚洲18禁久久av| 精品久久久久久久末码| 久久久久国内视频| 亚洲第一欧美日韩一区二区三区| 久久久久免费精品人妻一区二区| 免费看a级黄色片| 舔av片在线| 日本撒尿小便嘘嘘汇集6| 亚洲中文日韩欧美视频| 麻豆成人av在线观看| 国产欧美日韩一区二区三| 一个人观看的视频www高清免费观看| 欧美日韩福利视频一区二区| 国产久久久一区二区三区| 亚洲av五月六月丁香网| 成人国产一区最新在线观看| 在线观看美女被高潮喷水网站 | 99热这里只有精品一区| 亚洲av成人精品一区久久| 亚洲最大成人中文| 99久久久亚洲精品蜜臀av| 香蕉av资源在线| 成人无遮挡网站| 免费看日本二区| 在线国产一区二区在线| av天堂中文字幕网| 一进一出抽搐gif免费好疼| 五月伊人婷婷丁香| 九九热线精品视视频播放| 97热精品久久久久久| 老司机午夜福利在线观看视频| 亚洲中文日韩欧美视频| 特级一级黄色大片| 国产一级毛片七仙女欲春2| 午夜福利18| 啪啪无遮挡十八禁网站| 亚洲在线观看片| 我的老师免费观看完整版| 国产伦精品一区二区三区视频9| 91久久精品国产一区二区成人| 国产成人av教育| 中文资源天堂在线| 精品人妻1区二区| 亚洲av日韩精品久久久久久密| 亚洲成人久久爱视频| 丰满乱子伦码专区| 一级毛片久久久久久久久女| aaaaa片日本免费| 夜夜躁狠狠躁天天躁| 熟妇人妻久久中文字幕3abv| 国产男靠女视频免费网站| 噜噜噜噜噜久久久久久91| 在现免费观看毛片| 人妻丰满熟妇av一区二区三区| 黄色日韩在线| 国产午夜精品久久久久久一区二区三区 | eeuss影院久久| 色吧在线观看| 免费观看的影片在线观看| 久久久精品大字幕| 在线a可以看的网站| 在线观看一区二区三区| 乱人视频在线观看| 日韩有码中文字幕| 真实男女啪啪啪动态图| 久久香蕉精品热| 3wmmmm亚洲av在线观看| 亚洲成a人片在线一区二区| 亚洲精品在线美女| 成人无遮挡网站| 国产免费男女视频| 听说在线观看完整版免费高清| 男女那种视频在线观看| 久久这里只有精品中国| 久久精品国产99精品国产亚洲性色| 国产精品一区二区性色av| 色播亚洲综合网| 少妇的逼水好多| 久久中文看片网| 中出人妻视频一区二区| 91久久精品电影网| 久久性视频一级片| 在线观看免费视频日本深夜| 偷拍熟女少妇极品色| 看免费av毛片| 黄色女人牲交| 精品午夜福利视频在线观看一区| 久久人人精品亚洲av| 我要搜黄色片| 别揉我奶头 嗯啊视频| ponron亚洲| 最近视频中文字幕2019在线8| 如何舔出高潮| 深夜a级毛片| 亚洲人与动物交配视频| 成人毛片a级毛片在线播放| 欧美成人一区二区免费高清观看| 亚洲欧美日韩东京热| 国产精品三级大全| 亚洲在线自拍视频| 在线免费观看的www视频| 精品久久久久久成人av| 国产真实伦视频高清在线观看 | 看黄色毛片网站| 欧美黑人欧美精品刺激| 国产又黄又爽又无遮挡在线| 搡女人真爽免费视频火全软件 | 天美传媒精品一区二区| 一本综合久久免费| 欧美日韩中文字幕国产精品一区二区三区| 可以在线观看毛片的网站| 宅男免费午夜| 亚洲精品乱码久久久v下载方式| 亚洲美女黄片视频| 97超级碰碰碰精品色视频在线观看| 12—13女人毛片做爰片一| 日本 欧美在线| 久久精品国产亚洲av涩爱 | 乱码一卡2卡4卡精品| 岛国在线免费视频观看| 亚洲欧美日韩卡通动漫| 成人亚洲精品av一区二区| 黄色配什么色好看| 午夜免费成人在线视频| 亚洲精品粉嫩美女一区| 国产亚洲欧美98| 亚洲va日本ⅴa欧美va伊人久久| 午夜福利在线在线| 男女之事视频高清在线观看| 一卡2卡三卡四卡精品乱码亚洲| 婷婷亚洲欧美| 精品不卡国产一区二区三区| a级毛片a级免费在线| 国产探花在线观看一区二区| 丰满人妻一区二区三区视频av| 99热这里只有精品一区| 久久亚洲精品不卡| 欧美国产日韩亚洲一区| 少妇丰满av| 男人狂女人下面高潮的视频| 午夜影院日韩av| 热99re8久久精品国产| 一区二区三区高清视频在线| 欧美成狂野欧美在线观看| 99视频精品全部免费 在线| 免费人成视频x8x8入口观看| 日韩精品中文字幕看吧| 亚洲黑人精品在线| 激情在线观看视频在线高清| 成人午夜高清在线视频| 白带黄色成豆腐渣| av视频在线观看入口| 欧美激情国产日韩精品一区| 亚洲av第一区精品v没综合| 欧美日韩国产亚洲二区| 性色av乱码一区二区三区2| 午夜日韩欧美国产| 露出奶头的视频| 99精品在免费线老司机午夜| 长腿黑丝高跟| 免费观看精品视频网站| 国产精品三级大全| 午夜免费男女啪啪视频观看 | 国产一级毛片七仙女欲春2| 亚洲五月天丁香| 国产白丝娇喘喷水9色精品| 免费看美女性在线毛片视频| 日日摸夜夜添夜夜添av毛片 | 色视频www国产| 大型黄色视频在线免费观看| 亚洲人与动物交配视频| 人人妻,人人澡人人爽秒播| 麻豆成人午夜福利视频| 在线观看av片永久免费下载| 亚洲人与动物交配视频| av中文乱码字幕在线| 很黄的视频免费| 久久欧美精品欧美久久欧美| 亚洲欧美激情综合另类| 亚洲欧美日韩无卡精品| 色av中文字幕| 久久精品夜夜夜夜夜久久蜜豆| xxxwww97欧美| 免费在线观看影片大全网站| 亚洲av成人av| 日韩免费av在线播放| 天堂√8在线中文| or卡值多少钱| 国产亚洲欧美98| 亚洲国产精品合色在线| 少妇人妻一区二区三区视频| 日本免费a在线| 中文字幕精品亚洲无线码一区| 亚洲一区二区三区不卡视频| 少妇丰满av| 午夜激情福利司机影院| 人妻制服诱惑在线中文字幕| 天堂√8在线中文| 午夜激情欧美在线| 国产毛片a区久久久久| 美女高潮喷水抽搐中文字幕| 狂野欧美白嫩少妇大欣赏| 在线十欧美十亚洲十日本专区| 婷婷六月久久综合丁香| 久久久色成人| 亚洲欧美日韩东京热| 九色成人免费人妻av| 国产亚洲欧美98| 夜夜看夜夜爽夜夜摸| 国产亚洲av嫩草精品影院| 国产一区二区三区视频了| 麻豆国产av国片精品| 国产免费一级a男人的天堂| 99精品久久久久人妻精品| 久久热精品热| 最新在线观看一区二区三区| 欧美bdsm另类| 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 国产精品免费一区二区三区在线| 免费黄网站久久成人精品 | 精品久久久久久久久久免费视频| 亚洲国产欧洲综合997久久,| 成人精品一区二区免费| 丰满乱子伦码专区| 特级一级黄色大片| 男女视频在线观看网站免费| 久久精品91蜜桃| 亚洲成av人片免费观看| 国产精品一区二区性色av| 亚洲人成电影免费在线| 国产精品影院久久| 又爽又黄无遮挡网站| 中文字幕人成人乱码亚洲影| 久久精品国产亚洲av天美| 高清日韩中文字幕在线| 脱女人内裤的视频| 麻豆国产97在线/欧美| 亚洲在线自拍视频| 国产精品一区二区三区四区久久| 怎么达到女性高潮| 国产精品日韩av在线免费观看| 午夜免费男女啪啪视频观看 | 午夜福利18| 免费看日本二区| 日韩中字成人| 日本三级黄在线观看| 一进一出好大好爽视频| 亚洲久久久久久中文字幕| 亚洲精品在线观看二区| 一本久久中文字幕| 一区二区三区四区激情视频 | av中文乱码字幕在线| 亚洲av熟女| 人人妻人人看人人澡| 久久婷婷人人爽人人干人人爱| 无人区码免费观看不卡| 老熟妇乱子伦视频在线观看| 一二三四社区在线视频社区8| av黄色大香蕉| 日本免费一区二区三区高清不卡| 日本免费a在线| 国产又黄又爽又无遮挡在线| 国产精品久久久久久久电影| 欧美黑人欧美精品刺激| 一级av片app| 色哟哟哟哟哟哟| 日本 欧美在线| 欧美激情国产日韩精品一区| 亚洲熟妇中文字幕五十中出| 精品日产1卡2卡| 午夜影院日韩av| 能在线免费观看的黄片| 中文亚洲av片在线观看爽| 天美传媒精品一区二区| 看黄色毛片网站| 69av精品久久久久久| 国产精品亚洲美女久久久| 免费看美女性在线毛片视频| 国产乱人伦免费视频| 国模一区二区三区四区视频| 精品国产亚洲在线| 亚洲人成电影免费在线| 精华霜和精华液先用哪个| 级片在线观看| 国产精品三级大全| 亚洲最大成人中文| 国产亚洲av嫩草精品影院| 免费av不卡在线播放| 精品一区二区三区视频在线| 精品人妻视频免费看| 精品人妻一区二区三区麻豆 | 好男人电影高清在线观看| 免费看日本二区| 亚洲av.av天堂| 国产探花在线观看一区二区| 午夜亚洲福利在线播放| 亚洲中文字幕日韩| 亚洲欧美激情综合另类| 亚洲美女视频黄频| 天堂网av新在线| 18禁在线播放成人免费| 国产老妇女一区| av女优亚洲男人天堂| 无遮挡黄片免费观看| 国产久久久一区二区三区| 长腿黑丝高跟| 日韩国内少妇激情av| 亚洲欧美清纯卡通| 欧美一区二区精品小视频在线| 国产成人欧美在线观看| 在线免费观看的www视频| 欧美高清成人免费视频www| 一区二区三区四区激情视频 | 久久99热6这里只有精品| 草草在线视频免费看| 午夜精品一区二区三区免费看| av在线天堂中文字幕| 在线观看66精品国产| 久久久国产成人免费| 日本与韩国留学比较| 内地一区二区视频在线| 久久精品影院6| 两性午夜刺激爽爽歪歪视频在线观看| 免费观看的影片在线观看| av中文乱码字幕在线| 日本在线视频免费播放| a级毛片免费高清观看在线播放| 国产精品乱码一区二三区的特点| 亚洲av免费高清在线观看| 亚洲乱码一区二区免费版| 中文字幕人妻熟人妻熟丝袜美| 国产欧美日韩精品亚洲av| 国产午夜精品论理片| 性色avwww在线观看| 亚洲精品在线观看二区| 又爽又黄a免费视频| 露出奶头的视频| av福利片在线观看| 精品无人区乱码1区二区| 国产伦精品一区二区三区视频9| 国产激情偷乱视频一区二区| 九九热线精品视视频播放| 国产精品不卡视频一区二区 | 最新中文字幕久久久久| 国产成人av教育| 欧美又色又爽又黄视频| 久久久久性生活片| 亚洲成人久久性| 1024手机看黄色片| 999久久久精品免费观看国产| 国产精华一区二区三区| 999久久久精品免费观看国产| 在现免费观看毛片| 成人av一区二区三区在线看| 久久久国产成人免费| 中文字幕av成人在线电影| aaaaa片日本免费| 欧美zozozo另类| 波野结衣二区三区在线| 制服丝袜大香蕉在线| 91久久精品国产一区二区成人| 精品无人区乱码1区二区| 九九热线精品视视频播放| 精品人妻偷拍中文字幕| 午夜免费激情av| 日韩精品中文字幕看吧| www.999成人在线观看| 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 激情在线观看视频在线高清| 亚洲国产精品成人综合色| 一级黄色大片毛片| 午夜福利在线观看吧| 亚洲成人免费电影在线观看| 亚洲精品久久国产高清桃花| 欧美三级亚洲精品| 精品欧美国产一区二区三| 亚洲精品一卡2卡三卡4卡5卡| 搡老妇女老女人老熟妇| 免费av不卡在线播放| 高清毛片免费观看视频网站| 日本黄大片高清| 听说在线观看完整版免费高清| 一个人看的www免费观看视频| 久久久久九九精品影院| 国产极品精品免费视频能看的| 非洲黑人性xxxx精品又粗又长| 中文字幕人成人乱码亚洲影| 精品久久久久久久久久久久久| 精品午夜福利在线看| 免费在线观看日本一区| 噜噜噜噜噜久久久久久91| 成人高潮视频无遮挡免费网站| 亚洲国产精品成人综合色| 日韩中文字幕欧美一区二区| 能在线免费观看的黄片| 亚洲精品成人久久久久久| 亚洲天堂国产精品一区在线| 久久久久久国产a免费观看| 亚洲国产精品合色在线| 亚洲最大成人手机在线| 亚洲精品在线观看二区| 色尼玛亚洲综合影院| 一二三四社区在线视频社区8| 免费一级毛片在线播放高清视频| 我要搜黄色片| 亚洲av二区三区四区| 欧美黑人巨大hd| 午夜福利高清视频| 免费看日本二区| 宅男免费午夜| 真人做人爱边吃奶动态| 狠狠狠狠99中文字幕| 日本黄大片高清| 久久草成人影院| 高清日韩中文字幕在线| 9191精品国产免费久久| 精品久久久久久久末码| 91午夜精品亚洲一区二区三区 | a级毛片a级免费在线| 亚洲国产日韩欧美精品在线观看| 欧美日韩乱码在线| 免费无遮挡裸体视频| 亚洲精华国产精华精| 三级男女做爰猛烈吃奶摸视频| 亚洲av熟女| 黄色配什么色好看| 免费观看的影片在线观看| 国产极品精品免费视频能看的| 久久久久九九精品影院| 亚洲成人免费电影在线观看| 51国产日韩欧美| 少妇人妻一区二区三区视频| 尤物成人国产欧美一区二区三区|